Role of insurance, income, and affordability in human papillomavirus vaccination

American Journal of Managed Care

Volumn 18, Issue 6, 2012, Pages 320-330

  Pourat, Nadereh ^a   Jones, Jenna M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HEALTH SURVEY; HUMAN; INCOME; LOGISTIC REGRESSION ANALYSIS; MEDICAL CARE; NORMAL HUMAN; PAPILLOMAVIRUS INFECTION; PARENTAL ATTITUDE; PRIORITY JOURNAL; VACCINATION; WART VIRUS;

ADOLESCENT; ADULT; CHILD; FEMALE; HEALTH CARE COSTS; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INCOME; INSURANCE COVERAGE; INSURANCE, HEALTH; LOGISTIC MODELS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT SATISFACTION; YOUNG ADULT;

EID: 84864401591     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14(2):244-251. (Pubitemid 351213674)
2. Spurgeon SA, Johnston D, Pefole M, Fleishman V. Challenges in Vaccine Policy: A Case Study of the HPV Vaccine. Cambridge, MA: New England Healthcare Institute; August 2006. www.nehi.net/uploads/full.../hpv-report-final-color-8. 29.06.pdf. Accessed April 19, 2012.
3. The Henry J. Kaiser Family Foundation. California: cervical cancer incidence rate per 100,000 women by race/ethnicity, 2007. http://www. statehealthfacts.or/profileind.jsp?ind=474&cat=10&rgn=6. Accessed September 20, 2011.
4. The Henry J. Kaiser Family Foundation. HPV Vaccine: Implementation and Financing Policy in the U.S. Washington, DC: The Henry J. Kaiser Family Foundation; 2008.
5. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102(5A)(suppl):3-8. (Pubitemid 127695953)
6. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
7. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359(8):821-832.
8. Stanley M. Introduction: the human papillomavirus VLP vaccines. Gynecol Oncol. 2010;118(1)(suppl 1):S1.
9. Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc. 2009;84(10):864-870.
10. Castellsagué X, Schneider A, Kaufmann AM, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol. 2009;115(3)(suppl):S15- S23.
11. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180(5):1415-1423. (Pubitemid 29506440)
12. California Health Benefits Review Program. A Report to the 2007-2008 California State Legislature: Analysis of Assembly Bill 1429: Human Papillomavirus Vaccination. Oakland, CA: California Health Benefits Review Program; 2007.
13. Vetter KM, Geller SE. Moving forward: human papillomavirus vaccination and the prevention of cervical cancer. J Womens Health (Larchmt). 2007;16(9):1258-1268. (Pubitemid 350125868)
14. National Conference of State Legislatures. HPV vaccine. http://www.ncsl.org/default.aspx?tabid=14381. Updated March 2010. Accessed September 1, 2010.
15. Conroy K, Rosenthal SL, Zimet GD, et al. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Womens Health (Larchmt). 2009;18(10):1679-1686.
16. Dempsey AF, Davis MM. Overcoming barriers to adherence to HPV vaccination recommendations. Am J Manag Care. 2006;12(17)(suppl):S484-S491. (Pubitemid 46053399)
17. California Health Interview Survey. CHIS 2005 Methodology Series. Report One. Sample Design. http://www.chis.ucla.edu/pdf/CHIS2005-method1.pdf. Published April 2007. Accessed April 15, 2008.
18. Andersen RM, Davidson PL. Improving access to care in America: individual and contextual indicators. In: Andersen RM, Rice TH, Kominski GF, eds. Changing the U.S. Health Care System. 3rd ed. San Francisco, CA: Jossey Bass; 2007.
19. Anhang Price R, Tiro JA, Saraiya M, Meissner H, Breen N. Use of human papillomavirus vaccines among young adult women in the United States: an analysis of the 2008 National Health Interview Survey. Cancer. 2011;117(24):5560-5568.
20. Wong CA, Berkowitz Z, Dorell CG, Anhang Price R, Lee J, Saraiya M. Human papillomavirus vaccine uptake among 9- to17-year-old girls: National Health Interview Survey, 2008. Cancer. 2011;117(24):5612-5620.
21. Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev Med. 2009;48(5):426-431.
22. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2009. MMWR Morb Mortal Wkly Rep.2010;59(32):1018-1023.
23. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Morb Mortal Wkly Rep. 2010;59(36):1184]. MMWR Morb Mortal Wkly Rep. 2010;59(20):626-629.
24. Mast EE, Margolis HS, Fiore AE, et al Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part I: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16):1-23.
25. Mast EE, Weinbaum CM, Fiore AE; Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults [published correction appears in MMWR Morb Mortal Wkly Rep. 2007;56(42):1114]. MMWR Recomm Rep. 2006;55(RR-16):1-33.
26. Centers for Disease Control and Prevention (CDC). Hepatitis B vaccination - United States, 1982-2002. MMWR Morb Mortal Wkly Rep. 2002;51(25):549-552, 563.
27. Yeganeh N, Curtis D, Kuo A. Factors influencing HPV vaccination status in a Latino population; and parental attitudes towards vaccine mandates. Vaccine. 2010;28(25):4186-4191.
28. Read DS, Joseph MA, Polishchuk V, Suss AL. Attitudes and perceptions of the HPV vaccine in Caribbean and African-American adolescent girls and their parents. J Pediatr Adolesc Gynecol. 2010;23(4):242-245.
29. Bastani R, Glenn BA, Tsui J, et al. Understanding suboptimal HPV vaccine uptake among ethnic minority girls. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1463-1472.
30. Gerend MA, Magloire ZF. Awareness, knowledge, and beliefs about human papillomavirus in a racially diverse sample of young adults. J Adolesc Health. 2008;42(3):237-242.
31. Bynum SA, Brandt HM, Sharpe PA, Williams MS, Kerr JC. Working to close the gap: identifying predictors of HPV vaccine uptake among young African American women. J Health Care Poor Underserved. 2011;22(2):549-561.
32. Perkins RB, Pierre-Joseph N, Marquez C, Iloka S, Clark JA. Why do low-income minority parents choose human papillomavirus vaccination for their daughters? J Pediatr. 2010;157(4):617-622.
33. Daley EM, Vamos CA, Buhi ER, et al. Influences on human papillomavirus vaccination status among female college students. J Womens Health (Larchmt). 2010;19(10):1885-1891.
34. Zimet GD, Weiss TW, Rosenthal SL, Good MB, Vichnin MD. Reasons for non-vaccination against HPV and future vaccination intentions among 19-26 year-old women. BMC Women's Health.10(1):27.
35. Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstetrics Gynecol. 2008;111(5):1103-1110. (Pubitemid 351620344)
36. Gostin LO. Mandatory HPV vaccination and political debate. JAMA. 2011;306(15):1699-1700.